These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11491658)

  • 1. Osmotic stress-mediated activation of RET kinases involves intracellular disulfide-bonded dimer formation.
    Takeda K; Kato M; Wu J; Iwashita T; Suzuki H; Takahashi M; Nakashima I
    Antioxid Redox Signal; 2001 Jun; 3(3):473-82. PubMed ID: 11491658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.
    Kato M; Iwashita T; Takeda K; Akhand AA; Liu W; Yoshihara M; Asai N; Suzuki H; Takahashi M; Nakashima I
    Mol Biol Cell; 2000 Jan; 11(1):93-101. PubMed ID: 10637293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanism of activation and superactivation of Ret tyrosine kinases by ultraviolet light irradiation.
    Kato M; Iwashita T; Akhand AA; Liu W; Takeda K; Takeuchi K; Yoshihara M; Hossain K; Wu J; Du J; Oh C; Kawamoto Y; Suzuki H; Takahashi M; Nakashima I
    Antioxid Redox Signal; 2000; 2(4):841-9. PubMed ID: 11213488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein.
    Bongarzone I; Vigano E; Alberti L; Mondellini P; Uggeri M; Pasini B; Borrello MG; Pierotti MA
    Oncogene; 1999 Aug; 18(34):4833-8. PubMed ID: 10490816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation.
    Arlt DH; Baur B; Wagner B; Höppner W
    Oncogene; 2000 Jul; 19(30):3445-8. PubMed ID: 10918602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation.
    Bongarzone I; Vigano E; Alberti L; Borrello MG; Pasini B; Greco A; Mondellini P; Smith DP; Ponder BA; Romeo G; Pierotti MA
    Oncogene; 1998 May; 16(18):2295-301. PubMed ID: 9620546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of both extra- and intracellular cysteine targets of protein modification for activation of RET kinase.
    Akhand AA; Ikeyama T; Akazawa S; Kato M; Hossain K; Takeda K; Suzuki H; Takahashi M; Nakashima I
    Biochem Biophys Res Commun; 2002 Apr; 292(4):826-31. PubMed ID: 11944888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
    Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
    Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
    Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
    Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
    Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RET activation by germline MEN2A and MEN2B mutations.
    Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
    Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes.
    Castellone MD; Cirafici AM; De Vita G; De Falco V; Malorni L; Tallini G; Fagin JA; Fusco A; Melillo RM; Santoro M
    Oncogene; 2003 Jan; 22(2):246-55. PubMed ID: 12527893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
    Kato M; Takeda K; Kawamoto Y; Iwashita T; Akhand AA; Senga T; Yamamoto M; Sobue G; Hamaguchi M; Takahashi M; Nakashima I
    Cancer Res; 2002 Apr; 62(8):2414-22. PubMed ID: 11956105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
    Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
    Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas.
    Lanzi C; Borrello MG; Bongarzone I; Migliazza A; Fusco A; Grieco M; Santoro M; Gambetta RA; Zunino F; Della Porta G
    Oncogene; 1992 Nov; 7(11):2189-94. PubMed ID: 1437145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A redox-linked novel pathway for arsenic-mediated RET tyrosine kinase activation.
    Kato M; Takeda K; Hossain K; Thang ND; Kaneko Y; Kumasaka M; Yamanoshita O; Uemura N; Takahashi M; Ohgami N; Kawamoto Y
    J Cell Biochem; 2010 May; 110(2):399-407. PubMed ID: 20235151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation.
    Iwashita T; Asai N; Murakami H; Matsuyama M; Takahashi M
    Oncogene; 1996 Feb; 12(3):481-7. PubMed ID: 8637703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
    Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of RET autophosphorylation sites by mass spectrometry.
    Kawamoto Y; Takeda K; Okuno Y; Yamakawa Y; Ito Y; Taguchi R; Kato M; Suzuki H; Takahashi M; Nakashima I
    J Biol Chem; 2004 Apr; 279(14):14213-24. PubMed ID: 14711813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.